Clopidogrel "resistance"

Thrombosis and Haemostasis

Volumn 92, Issue 2, 2004, Pages 229-231

  Schrör, Karsten ^a   Weber, Artur Aron ^a   Hohlfeld, Thomas ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CLOPIDOGREL; ERYTHROMYCIN;

BLEEDING; BLOOD SAMPLING; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG RESPONSE; DRUG TRANSFORMATION; EDITORIAL; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; STROKE; THROMBOCYTE AGGREGATION INHIBITION;

EID: 4444250410     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th04-05-0305     Document Type: Editorial

References (20)

1. Roses S, Glaxo Chief. Our drugs do not work on most patients. In an interview with Steve Connor, Science Editor; Independent UK, December 08; 2003.
2. Mukherjee D, Topol EJ. Pharmacogenomics in cardiovascular diseases. Progr Cardiovasc Dis 2002; 44: 479-98.
3. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. Br Med J 2002; 324: 71-86.
4. Holmes MB, Sobel BE, Schneider DJ. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects. Am J Cardiol 1999; 84: 203-7.
5. Zimmermann N, Wenk A, Kim U, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003; 108: 542-7.
6. Weber A-A, Przytulski B, Schanz A, et al. Towards a definition of aspirin resistance: a typological approach. Platelets 2002; 13: 3740.
7. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting. Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-13.
8. Müller I, Besta F, Schulz C, et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89: 783-7.
9. Bachmann F, Savcic M, Hauert J, et al. Rapid onset of inhibition of ADP-induced platelet aggregation by a loading dose of clopidogrel. Eur Heart J 1996; 17 (Suppl): 263.
10. Gawaz M, Seyfarth M, Müller I, et al. Comparison of the effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent placement. Am J Cardiol 2001; 87: 332-6.
11. Müller I, Seyfarth M, Rüdiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001; 85: 92-3.
12. Steinhubl SR, Berger PB, Mann JT 3rd, et al. CREDO investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-20.
13. Kastrati A, Mehilli J, Schuhlen H, et al. Intracoronary stenting and antithrombotic regimen rapid early action for coronary treatment study investigators. N Engl J Med 2004; 350: 232-8.
14. Hochholzer W, Trenk D, Frundi D, et al. Ausmaß der Thrombozyteninhibition nach einer Initialdosis von 600 mg Clopidogrel und Prävalenz von Non-Respondern zum Zeitpunkt der Koronarintervention. Z Kardiol 2004: 93 (suppl 3):392.
15. McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: A review of prevalence, mechanisms and clinical significance. Thromb Haemost 2002; 88: 711-5.
16. Lau WC, Gurbel PA, Watkins PB, et al.. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidorel resistance. Circulation 2004; 109: r1-r6.
17. Taubert D, Kastrati A, Harlfinger S, et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004; 92: 311-6.
18. ++-levels. Thromb Res 1994; 75: 233-42.
19. Weber A-A, Meila D, Jacobs C, et al.. Low incidence of paradoxical platelet activation by glycoprotein IIb/IIIa inhibitors. Thromb Res 2002; 106: 25-9.
20. Soffer D, Moussa I, Harjai KJ, et al. Impact of anginal class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: Do we need more aggressive dosing regimens in unstable angina? Cathet Cardiovasc Intervent 2003; 59: 21-5.